Claritin (Loratadine) provides effective relief from seasonal allergy symptoms.

Package	Price	Per Item	Savings	Order
60 pills x 10 mg	$49.75	Only $0.83 per pill	You Save $0.00
90 pills x 10 mg	$59.53	Only $0.66 per pill	You Save $15.40
120 pills x 10 mg	$70.19	Only $0.58 per pill	You Save $29.70

Paroxetine (exchange names Seroxat , Paxil ) is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It was released in 1992 by the pharmaceutical institution GlaxoSmithKline. It is used to treat major depression, obsessive-compulsive, panic and societal anxiety disorders in adult outpatients.

The efficacy of paroxetine for depression is comparable to that of older tricyclic antidepressants with fewer side effects and earlier small toxicity. Differences with newer antidepressants are subtler and mostly confined to side effects. It shares the general side effects and contraindications of other SSRIs, with high rates of nausea, somnolence, and earthy side effects. Unlike two other popular SSRI antidepressants fluoxetine and sertraline, paroxetine is associated with a clinically noteworthy weight gain and statistically significant increase in the risk of suicidality in adults. Pediatric trials of paroxetine for slump did not demonstrate efficacy and showed an increase in the risk of harmful outcomes, including episodes of self-mischief and potentially suicidal behavior in the paroxetine group compared to placebo. Stopping paroxetine is associated with a stiff risk of discontinuation syndrome. Due to the increased risk of birth defects, pregnant women or women planning to develop pregnant are recommended to avoid paroxetine use.

Indications

Approved

Paroxetine is primarily second-hand to treat the symptoms of major depression, obsessive-compulsive disorder (OCD), post-damaging stress disorder (PTSD), panic disorder, generalized anxiety disorder (GAD), community phobia/social anxiety disorder, and premenstrual dysphoric disorder (PMDD).

It was the foremost antidepressant formally approved in the United States for the treatment of panic attacks.

According to the prescribing news provided by the manufacturer of Paxil brand of paroxetine GlaxoSmithKline and approved by the FDA, the effectiveness of paroxetine in foremost depressive disorder has been proven by six placebo-controlled clinical trials. For fear disorder, three 10-12-week studies indicated paroxetine superiority to placebo. Similarly, three 12-week trials for grown-up outpatients with social anxiety disorder demonstrated better response to paroxetine than to placebo.

Unapproved/off-portray/investigational

Moreover, studies have suggested that paroxetine can in fact be occupied in the treatment of premature ejaculation. In particular, intravaginal ejaculation latency time (IELT) rest to increase with a 6-13-fold, which was somewhat longer than those of a predessor.. the keep in a holding pattern achieved by the treatment with other SSRIs (fluvoxamine, fluoxetine, sertraline and citalopram). How, paroxetine taken acutely ("on demand") 3–10 hours before coitus resulted on the other hand in a "clinically irrelevant and sexually unsatisfactory" 1.5-fold delay of ejaculation and was inferior to clomipramine, which induced a fourfold obstruct.

There is also evidence that paroxetine may be effective in the treatment of compulsive gambling and hot flashes.

In two paired-blind studies of bipolar disorder patients, addition of paroxetine to a mood stabilizer had no advantages all through addition of placebo. Benefits of paroxetine prescription for diabetic neuropathy or chronic pressure headache. are uncertain.

Side effects

Among the common adverse effects associated with paroxetine treatment of dent and listed in the prescribing information, those with the greatest difference from placebo are nausea (26% on paroxetine vs 9% on placebo), somnolence (23% vs. 9% on placebo), ejaculatory brouhaha (13% vs. 0% on placebo), other male genital disorders (10% vs. 0% on placebo), asthenia (15% vs. 6% on placebo), sweating (11% vs. 2% on placebo), dizziness (13% vs. 6% on placebo), insomnia (13% vs. 6% on placebo), dry jaws (18% vs. 12% on placebo), constipation (14% vs. 9% on placebo), and tremor (8% vs. 2% on placebo). Other side effects comprehend headache, activation, weight gain, impaired memory and paresthesia.

General side effects are mostly proximate during the first 1–4 weeks while the body acquires a tolerance to the knock out, although once this happens, withdrawal can cause a rebound effect with symptoms re-emerging in an exaggerated aspect for very long periods of time. Almost all SSRIs are known to cause either one or more of these symptoms. A bodily receiving paroxetine treatment may experience a few, all, or none of the following side-effects, and most side-effects transfer disappear or lessen with continued treatment, though some may last everywhere in the duration. Side effects are also often dose-dependent, with fewer and/or less brutal symptoms being reported at lower dosages, and/or more severe symptoms being reported at higher dosages. Increases or changes in dosage may also justification symptoms to reappear or worsen.

On 9 December 2004 the European Medicines Agency's (EMEA) Commission for Medicinal Products for Human Use (CHMP) informed patients, prescribers and parents that paroxetine should not be prescribed to children. CHMP gave a signal to prescribers recommending close monitoring of adult patients at high risk of suicidal actions and/or suicidal thoughts. In other words, CHMP does not prohibit use of paroxetine with adults but stresses Draconian caution in actual usage. Also withdrawal reactions upon stopping treatment is mentioned and for that reason it is recommended to gradually reduce the dose over several weeks or months if decree of withdrawal is made.

A statistical analysis of paroxetine clinical trials in children and adolescents was conducted by the FDA in 2004. It indicated a statistically outstanding 2.7-fold raise in suicide behavior and ideation as compared to placebo. The craze for increased suicidality was observed in both trials for depression and for anxiety disorders.

Cases of akathisia and activation syndrome from been observed during paroxetine treatment.

Rarely serotonin syndrome, a sparse adverse effect may occur.

Paroxetine and other SSRIs have been shown to belief sexual side effects in most patients, both males and females.

Yearning or hypomania may occur as a serious side effect of paroxetine, effecting up to 8% of psychiatric patients treated. This side objective can occur in individuals with no history of mania but it is more likely to occur in those with bipolar or with a household history of mania.

Schmitt et al. (2001) suggested that paroxetine negatively affects cognition (i.e., IQ). In their writing-room, healthy participants given paroxetine for 14 days (20 mg for days 1–7 and 40 mg days 8–14) showed poorer withdrawal of words on day 14 compared to those receiving a placebo. Schmitt and co-workers, putting, did not account for significant differences in verbal recall at baseline between those receiving paroxetine and those receiving a placebo, differences which produced the outstanding finding. Furthermore, participants receiving paroxetine recalled as many words at baseline as they recalled on day 14. Consideration, the conclusion that paroxetine affects verbal recall was unwarranted.

Discontinuation syndrome

See also: SSRI discontinuation syndrome

Sundry psychoactive medications can cause withdrawal symptoms upon discontinuation from distribution. Evidence has shown that paroxetine has among the highest incidence rates and intensity of withdrawal syndrome of any medication of its class. Common withdrawal symptoms for paroxetine comprise nausea, dizziness, lightheadedness and vertigo; insomnia, nightmares and vivid dreams; feelings of energy in the body, as well as crying and anxiety. Liquid formulation of paroxetine is available and allows a completely gradual decrease of the dose, which may prevent discontinuation syndrome. Another support is to temporarily switch to fluoxetine, which has a longer half-life and thus decreases the savagery of discontinuation syndrome.

Paroxetine and pregnancy

According to the prescribing information provided by the producer of Paxil brand of paroxetine GlaxoSmithKline and approved by the FDA, "epidemiological studies have shown that infants born to women who had anything else trimester paroxetine exposure had an increased risk of cardiovascular malformations, primarily ventricular and atrial septal defects (VSDs and ASDs). In generalized, septal defects range from those that are symptomatic and may require surgery to those that are asymptomatic and may transform into spontaneously. If a patient becomes pregnant while taking paroxetine, she should be advised of the likely harm to the fetus. Unless the benefits of paroxetine to the mother justify continuing treatment, cogitation should be given to either discontinuing paroxetine therapy or switching to another antidepressant. For women who design to become pregnant or are in their first trimester of pregnancy, paroxetine should only be initiated after thoughtfulness of the other available treatment options." The American College of Obstetricians and Gynecologists also recommends that paroxetine use amongst pregnant women or women planning to become pregnant should be avoided. These conclusions are supported by multiple planned reviews and meta-analyses that found that, on average, the use of paroxetine during pregnancy is associated with with respect to 1.5-1.7-fold increase in congenital birth defects, in particular, heart defects. A brand-new non-systematic review in the Journal of Clinical Psychiatry, with the lead author, Salvatore Gentile, reporting to play a joke on received material or financial support from GSK, came to a different conclusion: "the teratogenic possibility of paroxetine that has been reported in some studies remains unproven." Gentile called for ample, epidemiologic, prospective, controlled studies on "mothers who accept taking paroxetine during pregnancy". Other reviews that conclude a strong of increased risks differ on whether the relatively small risks outweighs that of ailment relapse if discontinued; with some advocating discontinuation, of exercising caution, or more appropriate overview.

Neonatal withdrawal symptoms from Paxil have also been documented from mothers winning Paxil during pregnancy.

Pharmacology

Paroxetine is the most potent and one of the most identified with selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors (SSRI). This undertaking of the drug on brain neurons is thought to be responsible for its antidepressant effects.

Paroxetine is a phenylpiperidine acquired which is chemically unrelated to the tricyclic or tetracyclic antidepressants. In receptor binding studies, paroxetine did not evidence significant affinity for the adrenergic (α ₁ , α ₂ , β), dopaminergic, serotonergic (5HT ₁ , 5HT ₂ ), or histamine receptors of rat brain membrane. A muffled affinity for the muscarinic acetylcholine and noradrenaline receptors was evident. The predominant metabolites of paroxetine are essentially non-functioning as 5-HT reuptake inhibitors.

Formulations

Paroxetine CR (controlled release) was shown to be associated with a soften rate of nausea during the first week of treatment than paroxetine automatic release. However, the rate of treatment discontinuation due to nausea was not significantly different.. Since both Paxil and Paxil CR are unspecifically dosed once daily, the benefit of Paxil CR has been debated, especially affirmed the significant cost difference between (generic) Paxil and (brand-only) Paxil CR.

Dispute

For 10 years, GlaxoSmithKline's marketing of the drug stated that it was not habit forming. In 2002, the U.S. Subsistence and Drug Administration published a new product warning about the drug, and the International Union of Pharmaceutical Manufacturers Associations found GSK guilty of misleading the public about paroxetine and breaching two of the Society's codes of practice. The British Medical Journal quoted Charles Medawar, precede of Social Audit: "This drug has been promoted for years as acceptable and easy to discontinue.... The fact that it can cause intolerable withdrawal symptoms of the persuasion that could lead to dependence is enormously important to patients, doctors, investors, and the party. GlaxoSmithKline has evaded the issue since it was granted a license for paroxetine over 10 years ago, and the dope has become a blockbuster for them, generating about a tenth of their entire profits. The company has been promoting paroxetine directly to consumers as 'non-habit forming' for far too desire." Paroxetine prescribing information posted at GlaxoSmithKline now acknowledges the occurrence of a discontinuation syndrome, including consequential discontinuation symptoms.

A British Government parliamentary inquiry into a number of instruction and over the counter drugs noted problems with SSRI antidepressants including withdrawal, suicidal thoughts and other adverse effects. The survey found that paroxetine ( Paxil , Seroxat ) has, more commonly than other SSRI antidepressants, a least devastating impact on some users lives. Since the FDA approved paroxetine in 1992, approaching 5,000 U.S. citizens have sued GSK. Most of these people feel they were not sufficiently warned in betterment of the drug's side effects—particularly the withdrawal syndrome discussed above, after GSK had specifically advertised the slip someone a Mickey Finn as non-habit forming

In the UK since 2001 lawsuits have been filed representing people who accept been prescribed Seroxat. They allege that the drug has serious side effects, which GlaxoSmithKline downplayed in persistent information.

In early 2004, GSK agreed to settle charges of consumer fraud for $2.5 million (a teeny fraction of the over $2.7 billion in yearly Paxil sales at that ease). The legal discovery process also uncovered evidence of deliberate, systematic end of unfavorable Paxil research results. One of GSK's internal documents had said, "It would be commercially wrong to include a statement that efficacy had not been demonstrated, as this would damage the profile of paroxetine".

On January 29 2007, the BBC broadcast a fourth documentary in its Panorama series all over the drug Seroxat. This programme, entitled Secrets of the Drug Trials, focused on three GSK paediatric clinical trials on depressed children and adolescents. Text from the trials show that Seroxat could not be proven to work for teenagers. Also, one clinical litigation indicated that adolescents were six times more likely to become suicidal after fetching it.

The court documents released as a result of one of the lawsuits in October 2008 indicated that GSK "and/or researchers may tease suppressed or obscured suicide risk data during clinical trials" of paroxetine. One of the investigators, "Charles Nemeroff, ci-devant Chairman of the Department of Psychiatry at Emory University, was the first big name 'outed' ...In beginning October, Nemeroff resigned from Emory amid revelations that he had received floor $960,000 from GSK in 2006, yet reported less than $35,000 to the school. In the wake investigations revealed payments totaling more than $2.5 million from treat companies between 2000 and 2006, yet only a fraction was disclosed."

The suppression of unfavorable dig into findings on Paxil by GSK — and the legal discovery process that uncovered it — is the guinea-pig of Alison Bass's 2008 book Side Effects: A Prosecutor, a Whistleblower, and a Bestselling Antidepressant on Testing .

Sales

In 2006, paroxetine was the fifth-most prescribed antidepressant in the United States retail sell, with more than 19.7 million prescriptions. In 2007, sales had dropped degree to 18.1 million but paroxetine remained the fifth-most prescribed antidepressant in the U.S.

Footnotes

1. ^ Anderson IM (April 2000). "Discriminatory serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-enquiry of efficacy and tolerability". J Affect Disord 58 (1): 19–36. doi: 10.1016/S0165-0327(99)00092-0 . PMID 10760555 . http://linkinghub.elsevier.com/save/pii/S0165-0327(99)00092-0 .  
2. ^ http://cat.inist.fr/?aModele=afficheN&cpsidt=972015
3. ^ Papakostas GI (2008). "Tolerability of up to date antidepressants". J Clin Psychiatry 69 Suppl E1 : 8–13. PMID 18494538.  
4. ^ Barbui C, Furukawa TA, Cipriani A (January 2008). "Effectiveness of paroxetine in the treatment of percipient major depression in adults: a systematic re-examination of published and unpublished details from randomized trials". CMAJ 178 (3): 296–305. doi: 10.1503/cmaj.070693 . PMID 18227449.  
5. ^ ^{a b} Hammad TA (2004-08-16). "Periodical and evaluation of clinical data: relationship between psychotropic drugs and pediatric suicidality" (PDF). Junction Meeting of the Psychopharmacologic Drugs Advisory Committee and Pediatric Advisory Committee. September 13 - 14, 2004. Briefing Facts. . FDA. 30 . http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Scrutiny.pdf . Retrieved on 2009-01-27 .  
6. ^ Hammad TA, Laughren T, Racoosin J (March 2006). "Suicidality in pediatric patients treated with antidepressant drugs". Roguish. Gen. Psychiatry 63 (3): 332–9. doi: 10.1001/archpsyc.63.3.332 . PMID 16520440.  
7. ^ "Report of the CSM expert working group on the safety of exacting serotonin reuptake inhibitor antidepressants" (PDF). MHRA. 2004-12 . http://www.mhra.gov.uk/snug harbor a comfortable/groups/pl-p/documents/drugsafetymessage/con019472.pdf . Retrieved on 2009-02-17 .  
8. ^ ^{a b} Haddad P (2001). "Antidepressant discontinuation syndromes". Hallucinogenic Saf 24 (3): 183–97. doi: 10.2165/00002018-200124030-00003 . PMID 11347722.  
9. ^ http://www.bmj.com/cgi/content/full/324/7332/260
10. ^ Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Shackles A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU (2005). "Evidence-based guidelines for the pharmacological treatment of worry disorders: recommendations from the British Association for Psychopharmacology". Journal of Psychopharmacology 19 (6): 567–596. doi: 10.1177/0269881105059253 . PMID 16272179.  
11. ^ D Baldwin, J Bobes, DJ Stein, I Scharwachter and M Faure (1999). "Paroxetine in community phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled go into. Paroxetine Study Group". The British Journal of Psychiatry 175 : 120–126. doi: 10.1192/bjp.175.2.120 . PMID 10627793.  
12. ^ Yonkers KA, Gullion C, Williams A, Novak K, Bustle AJ. (1996). "Paroxetine as a treatment for premenstrual dysphoric disorder". Journal of Clinical Psychopharmacology. 16 (1): 3–8. doi: 10.1097/00004714-199602000-00002 . PMID 8834412.  
13. ^ Turner, Francis Joseph (2005). Collective Work Diagnosis in Contemporary Practice . Oxford University Press US. ISBN 019516878X.  
14. ^ ^{a b c d e f} "PAXIL (paroxetine hydrochloride) Tablets and Articulated Suspension: PRESCRIBING INFORMATION". written at Research Triangle Park, NC (PDF). GlaxoSmithKline. August 2007 . http://us.gsk.com/products/assets/us_paxil.pdf . Retrieved on 2007-08-14 .  
15. ^ Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B (1998). "Effectuate of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled meditate on with fluoxetine, fluvoxamine, paroxetine, and sertraline". Journal of clinical psychopharmacology 18 (4): 274–81. doi: 10.1097/00004714-199808000-00004 . PMID 9690692.  
16. ^ Waldinger MD, Zwinderman AH, Olivier B (2001). "SSRIs and ejaculation: a dual-blind, randomized, fixed-dose study with paroxetine and citalopram". Daily of clinical psychopharmacology 21 (6): 556–60. doi: 10.1097/00004714-200112000-00003 . PMID 11763001.  
17. ^ ^{a b} Waldinger MD, Zwinderman AH, Olivier B (2004). "On-demand treatment of hasty ejaculation with clomipramine and paroxetine: a randomized, double-blind decided-dose study with stopwatch assessment". Eur. Urol. 46 (4): 510–5; discussion 516. doi: 10.1016/j.eururo.2004.05.005 . PMID 15363569.  
18. ^ Kim SW, Assign JE, Adson DE, Shin YC, Zaninelli R (2002). "A double-blind placebo-controlled scrutiny of the efficacy and safety of paroxetine in the treatment of pathological gambling". Journal of Clinical Psychiatry 63 (6): 501–507. PMID 12088161. post date category title/description 03.29.2009 Articles 40 Cost Mg Prilosec 03.29.2009 Articles 40 Celexa Mg 03.29.2009 Articles 40 Cal Movie Shoot 03.29.2009 Articles 40 And Taking Clomid 03.29.2009 Articles 4 Viagra

    Post Comments

    Name Email Your Comments